HELP — Cybin Inc.

Cybin Inc. , a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$413.0M

P/E Ratio

-2.09

Beta

0.79

52-Week Range

4.81-10.7199

Dividend Yield

$0.00

CEO

Eric So

Employees

50

IPO Date

Sep 13, 2019

Exchange

AMEX